Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $94.9 million.

  • Cytokinetics' Cash & Equivalents rose 377.05% to $225.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.5 million, marking a year-over-year increase of 377.05%. This contributed to the annual value of $94.9 million for FY2024, which is 16.35% down from last year.
  • Latest data reveals that Cytokinetics reported Cash & Equivalents of $94.9 million as of FY2024, which was down 16.35% from $113.4 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Cash & Equivalents peaked at $113.4 million during FY2023, and registered a low of $67.2 million during FY2022.
  • Its 3-year average for Cash & Equivalents is $91.8 million, with a median of $94.9 million in 2024.
  • In the last 5 years, Cytokinetics' Cash & Equivalents spiked by 127.77% in 2020 and then slumped by 40.37% in 2022.
  • Over the past 5 years, Cytokinetics' Cash & Equivalents (Yearly) stood at $83.0 million in 2020, then surged by 35.77% to $112.7 million in 2021, then slumped by 40.37% to $67.2 million in 2022, then skyrocketed by 68.79% to $113.4 million in 2023, then decreased by 16.35% to $94.9 million in 2024.